Evolocumab on top of empagliflozin improves endothelial function of individuals with diabetes: randomized active-controlled trial.

ABSTRACT:

Background

Sodium-glucose cotransporter 2 inhibitors (SGLT2i) improve endothelial dysfunction and reduce cardiovascular events in individuals with type 2 diabetes (T2D). Proprotein convertase subtilisin/kexin 9 (PCSK9i) inhibitors reduce cardiovascular events in high-risk patients. Whether the addition of PCSK9i to SGLT2i treatment adds benefits is not known.

Objectives

To assess the PCSK9-i effect on the endothelial function of T2D individuals under treatment with SGLT2-i.

Methods

Individuals with T2D were randomized in a 1:1 ratio to a 16-week treatment with either empagliflozin (E) or empagliflozin plus evolocumab (EE). The primary endpoint was post-treatment change from baseline in flow-mediated dilation (FMD) at 1-min. Secondary outcomes included changes in plasm

SUBMITTER: Sposito AC 

PROVIDER: S-EPMC9356512 | biostudies-literature | 2022 Aug

REPOSITORIES: biostudies-literature